Published in N Engl J Med on October 14, 2010
The economic value of personalized medicine tests: what we know and what we need to know. Genet Med (2013) 1.40
Integrating economic evaluation methods into clinical and translational science award consortium comparative effectiveness educational goals. Acad Med (2011) 1.30
The ethics and reality of rationing in medicine. Chest (2011) 1.24
The Effect of Budgetary Restrictions on Breast Cancer Diagnostic Decisions. Manuf Serv Oper Manag (2012) 1.08
Ethical priority setting for universal health coverage: challenges in deciding upon fair distribution of health services. BMC Med (2016) 1.08
Cost utility analysis of reverse total shoulder arthroplasty. J Shoulder Elbow Surg (2013) 0.89
Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst (2011) 0.89
Relative effectiveness and the European pharmaceutical market. Eur J Health Econ (2011) 0.87
Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2012) 0.84
HTA Implementation Roadmap in Central and Eastern European Countries. Health Econ (2016) 0.84
Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. Open Rheumatol J (2012) 0.83
Comparative effectiveness research in cancer: what has been funded and what knowledge gaps remain? J Natl Cancer Inst (2013) 0.82
Assessment of the cost-effectiveness and clinical outcomes of a fourth-generation synchronous telehealth program for the management of chronic cardiovascular disease. J Med Internet Res (2014) 0.80
Cost-Effectiveness of Cardiac Radiosurgery for Atrial Fibrillation: Implications for Reducing Health Care Morbidity, Utilization, and Costs. Cureus (2016) 0.78
Health Economics Information in Wound Care: The Elephant in the Room. Adv Wound Care (New Rochelle) (2013) 0.78
Capsule Commentary on Michaelidis et al., Cost-Effectiveness of Decision Support Strategies in Acute Bronchitis. J Gen Intern Med (2016) 0.78
Valuation of Child Behavioral Problems from the Perspective of US Adults. Med Decis Making (2015) 0.77
Climate and cultural aspects in intensive care units. Crit Care (2011) 0.77
Life, liberty, and the pursuit of quality-adjusted life-years after pancreatic cancer surgery. World J Surg (2011) 0.75
Cost-effectiveness modelling of percutaneous coronary interventions in stable coronary artery disease. World J Cardiol (2015) 0.75
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat (2016) 0.75
Hurdles and delays in access to anti-cancer drugs in Europe. Ecancermedicalscience (2014) 0.75
Ethical Dilemmas in Postnatal Treatment of Severe Congenital Hydrocephalus. Camb Q Healthc Ethics (2016) 0.75
Current challenges in health economic modeling of cancer therapies: a research inquiry. Am Health Drug Benefits (2014) 0.75
Cost-effectiveness Assessment of Cardiac Interventions: Determining a Socially Acceptable Cost Threshold. Interv Cardiol (Lond) (2015) 0.75
Quality of life as an outcome of opioid use disorder treatment: A systematic review. J Subst Abuse Treat (2017) 0.75
Is the US "leading from behind" on health policy? Eur J Health Econ (2013) 0.75
Pleurodesis with Thulium Cyber Laser versus talc poudrage: a comparative experimental study. Lasers Med Sci (2016) 0.75
Impact of old age on patient-report outcomes and cost utility for anterior cervical discectomy and fusion surgery for degenerative spine disease. Eur Spine J (2016) 0.75
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med (2014) 3.57
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
The global cost of nonoptimal blood pressure. J Hypertens (2009) 2.00
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis (2005) 1.64
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Outcomes and costs of acute treatment of traumatic brain injury. J Trauma (2002) 1.44
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Uncertainty and patient heterogeneity in medical decision models. Med Decis Making (2010) 1.38
Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. AJR Am J Roentgenol (2008) 1.37
Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976) (2011) 1.36
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol (2009) 1.34
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making (2005) 1.28
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
How much are Americans willing to pay for a quality-adjusted life year? Med Care (2008) 1.26
Economic burden of childhood autism spectrum disorders. Pediatrics (2014) 1.26
Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) (2005) 1.25
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med (2002) 1.21
Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health (2006) 1.17
Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ (2006) 1.14
When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ (2004) 1.14
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med (2011) 1.14
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr (2002) 1.13
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. Radiology (2008) 1.13
Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13
Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women. BMC Pregnancy Childbirth (2009) 1.12
A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One (2011) 1.11
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 1.11
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med (2002) 1.11
Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health (2007) 1.09
Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS (2008) 1.09
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health (2007) 1.06
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther (2002) 1.04
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS (2012) 1.03
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health (2004) 1.02
More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood) (2013) 1.01
Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler (2003) 1.01
Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J (2007) 1.01
Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr (2005) 1.01
Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer (2007) 1.01
The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. Vaccine (2005) 1.01
Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health (2011) 1.01
Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circ Cardiovasc Qual Outcomes (2014) 1.00
Medicare and medical technology--the growing demand for relevant outcomes. N Engl J Med (2010) 1.00
Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids. Int J Technol Assess Health Care (2009) 1.00
Can we better prioritize resources for cost-utility research? Med Decis Making (2005) 0.99
The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. Med Decis Making (2002) 0.98
Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther (2005) 0.98
A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr (2008) 0.96
Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med (2006) 0.96
Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). J Med Econ (2013) 0.95
Medicare's enduring struggle to define "reasonable and necessary" care. N Engl J Med (2012) 0.94
Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology (2004) 0.94
Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg (2003) 0.93